Abstract: A pill dispenser is provided with a floor, a rotor rotatably coupled adjacent the floor, a base coupled to the rotor, and an indexing mechanism coupled to the rotor to index the rotor in a rotational direction relative to the base to a plurality of index positions. The floor is adapted to be coupled to a shell to define an inner cavity for receiving pills. The floor has a funneled opening extending therethrough. The rotor has a plurality of pill receptacles extending from a top surface to a bottom surface and a plurality of corresponding separation ramps. Each separation ramp extends from the top surface downward to connect with one side of the corresponding pill receptacle. In each of the index positions, one of the pill receptacles aligns with an exit of the funneled opening and another of the pill receptacles aligns with a pill-dispense opening of the base.

Abstract: An improved baby bottle assembly that glows in the dark structured and arranged to be located without having to turn on the light, which may make a baby become wide awake. The bottle will also play a soothing melody, to help ease the baby back to sleep.

Abstract: The present invention is directed to a dental composition, and specifically to an improved composition for endodontic instruments useful for filling root canals or sealing.

Abstract: An organic-inorganic composite filler contains: inorganic aggregate particles formed by aggregation of inorganic primary particles with an average particle diameter of 10 to 1000 nm; an organic resin phase including a cured polymer of a polymerizable monomer covering surfaces of the inorganic primary particles and bonding the inorganic primary particles to each other, and a water absorbing resin; and aggregation gaps with a volume of micropores formed between parts of the organic resin phase of 0.01 to 0.30 cm3/g in pore volume measurement within a pore diameter range of 1 to 500 nm, as measured by a mercury intrusion technique. In a cross section passing through the centers of the inorganic aggregate particles, based on 100 measured inorganic particles, there are 10 or less inorganic aggregate particles having a macro void with a maximum width of at least 1 ?m.

Abstract: Zirconia dental ceramics exhibiting opalescence and having a grain size in the range of 10 nm to 300 nm, a density of at least 99.5% of theoretical density, a visible light transmittance at or higher than 45% at 560 nm, and a strength of at least 800 MPa.

Abstract: The invention relates to a dental composition comprising polymerizable monomer (1), initiator component(s), filler component(s) in an amount of more than about 20 wt.-%, wt.-% with respect to the whole weight of the composition, the polymerizable monomer (1) being characterized as follows: having exactly two (meth)acrylate reactive moieties, having an unsymmetrical backbone as linkage between the (meth)acrylate reactive moieties, the two (meth)acrylate reactive moieties being attached onto the unsymmetrical monomer backbone as alkyl esters, the unsymmetrical backbone comprising one aromatic moiety of the phenolic type, the polymerizable monomer (1) not containing an acidic moiety, other atoms than carbon, hydrogen, and oxygen, bisphenol moieties. The invention also relates to the use of the dental composition as or for producing a dental filling material, crown and bridge material, inlay, onlay, veneer or dental mill blank.

Abstract: The present invention relates to a stable emulsion, ready for use, of fat-soluble vitamins or carotenoids, a process for the preparation thereof, and the use thereof as addition to animal feeds, human foods and dietary supplements, and cosmetic and pharmaceutical compositions.

Abstract: A solid or hollow particle ranging from 0.001 to 200 microns in diameter coated with Indium Tin Oxide (“ITO”) and a topical composition containing same as well as a method for protecting skin against IR radiation.

Abstract: A cosmetic agent for dyeing keratin fibers, in particular human hair, includes a combination of a cross-linked, aminated siloxane polymer, a specific non-ionic surfactant, and at least one oxidation dye intermediate and/or one direct dye, wherein the use of the combination of cross-linked, aminated siloxane polymer and non-ionic surfactant leads to an increase in the color intensity.

Abstract: The present disclosure relates to hair care compositions such as hair restructuring compositions comprising a combination of restructuring components. The compositions are unique because they dramatically improve the quality and durability of hair, especially chemically treated hair. Typically, the compositions include: (a) one or more amines selected from the group consisting of diamines, polyamines, alkylamines, alkanolamines, and mixtures thereof; (b) one or more unsaturated carboxylic acids of formula (I): wherein R1 is a linear or branched C2-C10 alkenyl group; R2 is a linear or branched C1-C10 alkyl group; and R3 is (meth)acryloyloxy; and (c) a cosmetically acceptable carrier.

Abstract: Compounds, and agents for oxidatively changing the color of keratinic fibers that include such compounds, in particular human hair, in a cosmetic carrier. The compounds are at least one oxidation dye precursor product of formula (I) and/or physiologically acceptable salt thereof, in which R1, R2, R3, R4 independently of one another, stand for a hydrogen atom, a C1-C6 alkyl group, a C2-C6 alkenyl group, a hydroxy-(C1-C6)-alkyl group, a polyhydroxy-(C2-C6)-alkyl group, or a C1-C6-alkoxy-C2-C6-alkyl group, n stands for an integer from 2 to 6, and Z stands for an aromatic or aliphatic heterocycle or for an aromatic or aliphatic carbocycle.

Abstract: Cosmetic agents and methods for temporarily shaping keratin-containing fibers using the cosmetic agents are provided herein. In one embodiment, a cosmetic agent for temporarily shaping keratinic fibers includes a cosmetic preparation. The cosmetic preparation contains at least one copolymer a1) composed of at least the following monomer units: (meth)acrylic acid, (meth)acrylic acid alkyl ester, and (meth)acrylic acid hydroxyalkyl ester. The cosmetic preparation further contains at least one copolymer a2) composed of at least the following monomer units: N-tert-octylacrylamide, acrylic acid, and ethyl acrylate. The amount by weight of copolymers a1) and a2) in the total weight of the cosmetic preparation amounts to about 1.0 to about 10 by weight.

Abstract: The present invention relates to dentifrice compositions, in particular, toothpaste compositions, containing extracts of Nigella sativa, or black seed oil, and methods of preparing and using the same.

Abstract: A composition for applying to skin in need of treatment for skin barrier restoration, hydration and moisturization, the composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin. Also provided are methods for treating skin in need of skin barrier treatment, methods of treating skin to reduce the signs of aging and methods of treating skin to reduce the signs of inflammation with a composition comprising extracts of Ampelopsis grossedentata and Albizia julibrissin.

Abstract: An anti-dandruff composition comprising an Epilobium angustifolium extract, methods of use thereof and kits using same.

Abstract: Compositions derived from an extract of Amorphophallus konjac and methods for their use in the treatment of skin conditions. The compositions of the invention find use in maintaining the health of the skin and treating a variety of skin conditions, including wrinkles and fine lines, loss of skin tone, and hyperpigmentation. Without being limited to any particular theory or mechanism, the compositions of the invention treat skin conditions through the inhibition of enzymes, including but not limited to, collagenase, elastase and tyrosinase.

Abstract: Disclosed are methods of treating skin with topical skin compositions comprising at least one plant extract.

Abstract: A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: any amount or form of fucoidan, any amount or form of beta glucan; and any amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance of the skin is improved.

Abstract: The present invention provides methods for impregnating a porous carrier with an active pharmaceutical ingredient (“AP”), the methods comprising steps: a) dissolving at least one API in a solvent to form an API solution; b) contacting a porous carrier with the at least one API of step (a) in a contactor to form an API impregnated porous carrier; and c) drying the at least one API impregnated porous carrier.

Abstract: A pharmaceutical formulation is disclosed which includes an acrylic acid polymer and boric acid at a pH of less then about 5.0 and more than about 2.0.

Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.

Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.

Abstract: Provided are liposomes encapsulating mupirocin, with particular benefit for systemic therapeutically effective delivery. Also provided herein are pharmaceutical compositions including the liposomes and methods of using them. The liposomes include a lipid membrane and an intraliposomal compartment, the intraliposomal compartment encapsulating mupirocin, at least one cyclodextrin compound and a pH dependent ionizable anion, e.g. acetate.

Abstract: The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.

Abstract: The present invention provides administrable microparticles in vivo through a medical conduit, a composition comprising the same, and a manufacturing method therefor. The microparticles of the present invention have an advantage that a clogging phenomenon does not occur for an endoscopic administration through a spray apparatus.

Abstract: Provided is an orally disintegrating tablet which shows high stability of the active ingredients (acetylsalicylic acid and PPI), and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. A multiple-unit type orally disintegrating tablet containing enteric-coated micro granules containing acetylsalicylic acid, enteric-coated micro granules containing a proton pump inhibitor, and an additive, wherein an enteric coating layer of the enteric-coated micro granules containing acetylsalicylic acid contains an aqueous enteric polymer base and a sustained-release base.

Abstract: A composition for manufacture of hard hydroxypropyl methyl cellulose capsules comprising a film forming material of hydroxypropyl methyl cellulose having a methoxy content of 27.0-30.0% (w/w), and a hydroxypropoxy content of 4.0-7.5% and as a 2% weight solution, a viscosity of 3.5-6.0 cPs at 20° C., dipping compositions, process for manufacture of hard hydroxypropyl methyl cellulose capsules according to a dip coating process and hard capsule shells.

Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).

Abstract: Provided are a poorly water-soluble drug delivery system, a method of preparing the same, a method of delivering a poorly water-soluble drug using the same, and a pharmaceutical composition including the same as an effective component, and more particularly, a poorly water-soluble drug delivery system aiming cancer cell specific targeting, which may variously control the kind of a cancer cell targeting material capable of specifically reacting to an antigen overexpressed in a cancer cell, thereby binding to the surface of the poorly water-soluble drug delivery system, and variously control the kind of a poorly water-soluble drug encapsulated therein depending on the kind of cancer and a therapeutic purpose, thereby being effectively applicable to a cancer treatment method.

Abstract: Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.

Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.

Abstract: A composition and method are disclosed for optimizing sperm survival and function for couples suffering from male infertility by stimulating and increasing the female sexual partner's vaginal lubrication. An increased amount of vaginal transudate is produced in the female by the topical vulval application of a composition containing menthol or a related cooling compound. The resulting increased amount of vaginal transudate can support the function and viability of the spermatozoa in the hostile vaginal environment and ultimately in the cervical mucus to both capacitate sperm in vivo and to provide a medium for gradient sperm differentiation in the vagina and cervix. The inventive composition and method provides a means to compensate for male infertility caused by abnormal semen quality in order for a couple to successfully achieve conception.

Abstract: Provided herein is a drug delivery system for curcumin comprising fibrinogen, thrombin and curcumin.

Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.

Abstract: The present invention provides pharmaceutical formulations of levorotatory-epinephrine, l-epinephrine, more potent and less toxic than existing pharmaceutical formulations of epinephrine, along with methods of producing and using these pharmaceutical formulations of l-epinephrine, including autoinjection for treating anaphylaxis.

Abstract: Provided herein are compositions and methods for treating or preventing infection.

Abstract: The present invention relates to linear guanidine derivatives, methods of preparation, uses and pharmaceutical compositions thereof. The compounds of Formulas 1 or 2 exhibit high antimicrobial activity against Gram positive and Gram negative bacteria.

Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Abstract: This disclosure provides generally for antimicrobial compositions and methods of use comprising an anthocyanin, an anthocyanidin or metabolites thereof. Methods for promoting healing of a wound using these compositions are also disclosed. These compositions have broad spectrum antimicrobial activity and are safe for human and animal uses. Further, these compositions are safe for medical uses and industrial uses as antiseptic preparations to reduce or prevent microbial growth, including killing bacterial biofilms.

Abstract: A method of preventing and/or treating cancer in a subject is provided. The method includes administering to the subject a composition comprising an effective amount of an active agent selected from the group consisting of aurin tricarboxylic acid (ATA), aurin quadracarboxylic acid (AQA), aurin hexacarboxylic acid (AHA), aurin tricarboxylic acid complex (ATAC), and pharmaceutically acceptable salts thereof. The method excludes administration of components of crude aurin tricarboxylic acid greater than or equal to 1 kilodalton in molecular weight.

Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

Abstract: A medicament to be applied as an external preparation for therapeutic treatment of a local symptom of a neuropathic disease, which contains gabapentin or pregabalin in the form of an aqueous solution.

Abstract: Disclosed herein are compositions for use in treating anxiety, inflammatory conditions, fertility-related disorders, for increasing cognitive performance and managing weight comprising 10-Hydroxy-2-decenoic acid or a derivative thereof and preferably at least one polyunsaturated fatty acid. The preferred polyunsaturated fatty acid is DHA.

Abstract: There is provided a condom having a coating or deposit of a composition which includes a physiologically-active agent such as glyceryl trinitrate, wherein the condom has been treated with a neutralising or acidic material such that the condom, when immersed in water, results in the water having a pH of 7 or less. The condom may be treated with an acidic slurry of dusting powder. Also provided is a process for the manufacture of condoms, in which the process includes the steps of: 1) treating the formed condoms with a neutralising or acidic material; and 2) thereafter applying to the condoms a composition including a physiologically-active agent such as glyceryl trinitrate, wherein the condoms, when immersed in water, results in the water having a pH of 7 or less.

Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma. Chlorogenic acid according to the present invention has an inhibitory action against oligodendroglioma, and can inhibit the growth of brain tumor stem cells, thus can partly substitute chemoradiation. Chlorogenic acid can alleviate the unwell response of patients caused by chemoradiation, and become a new medicinal therapeutic means and choose for treatment of oligodendroglioma.